Atezolizumab and bevacizumab combination fails to meet primary endpoint in phase III IMagyn050 trial trial in patients with newly-diagnosed advanced ovarian cancer

Phase III study showed addition of atezolizumab to bevacizumab, paclitaxel and carboplatin did not meet primary endpoint of progression-free survival. However, as data for overall survival is not yet mature, the company plans to continue trial until next planned analysis.

Biospace Inc.